BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 20068279)

  • 1. [IgM-lambda multiple myeloma presenting with systemic amyloidosis].
    Higeta D; Yokohama A; Osaki Y; Tahara K; Mawatari M; Sekigami T; Koiso H; Saito T; Uchiumi H; Handa H; Karasawa M; Murakami H; Hirato J; Tsukamoto N; Nojima Y
    Rinsho Ketsueki; 2009 Dec; 50(12):1711-4. PubMed ID: 20068279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of multiple myeloma--associated amyloidosis by interferon-alpha, dimethyl sulfoxide, and VAD (vincristine, adriamycin, and dexamethasone).
    Ichida M; Imagawa S; Ohmine K; Komatsu N; Hatake K; Ozawa K; Miura Y
    Int J Hematol; 2000 Dec; 72(4):491-3. PubMed ID: 11197218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
    Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
    Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
    Nozza A; Siracusano L; Armando S
    Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of gastric amyloidosis developing into Bence-Jones type multiple myeloma, treated effectively by cyclo-VAMP chemotherapy].
    Ayabe T; Maekawa I; Ashida T; Taruishi M; Shibata Y; Namiki M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2399-403. PubMed ID: 8259860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.
    SAWADA T; NAJIMA Y; OHASHI K; KATO I; MIYAZAWA M; NAKANO M; KOBAYASHI T; YAMASHITA T; AKIYAMA H; SAKAMAKI H
    Rinsho Ketsueki; 2009 Nov; 50(11):1635-40. PubMed ID: 20009440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
    Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
    Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
    Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
    Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
    Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Harousseau JL; Attal M; Avet-Loiseau H; Marit G; Caillot D; Mohty M; Lenain P; Hulin C; Facon T; Casassus P; Michallet M; Maisonneuve H; Benboubker L; Maloisel F; Petillon MO; Webb I; Mathiot C; Moreau P
    J Clin Oncol; 2010 Oct; 28(30):4621-9. PubMed ID: 20823406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
    Warzocha K; Kraj M; Pogłód R; Kwaśniak B
    Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
    [No Abstract]   [Full Text] [Related]  

  • 15. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New treatment strategies for multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
    [No Abstract]   [Full Text] [Related]  

  • 17. [Rapidly progressive AL amyloidosis in a patient with relapsed multiple myeloma after achieving a complete response to tandem autologous PBSCT].
    Yagi H; Ozaki S; Sekimoto E; Shibata H; Shigekiyo T; Satake N
    Rinsho Ketsueki; 2013 Dec; 54(12):2171-6. PubMed ID: 24452148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
    Hughes M; Micallef-Eynaud P
    Clin Lab Haematol; 2006 Aug; 28(4):267-9. PubMed ID: 16898968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.
    Samanez C; Domingo A; Cibeira MT; Miquel R; Soler M; Bladé J
    Eur J Haematol; 2006 Jan; 76(1):83-5. PubMed ID: 16343276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.